Interactions of staphylokinase with human platelets

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Recombinant staphylokinase (SakSTAR) is a plasminogen activator with potential thrombolytic applications.
• Understanding its interaction with human platelets is crucial for assessing its safety and efficacy.
• Previous studies have not fully elucidated the effects of SakSTAR on platelet function.

Purpose of the Study:

• To investigate the interactions between recombinant staphylokinase (SakSTAR) and human platelets.
• To evaluate the impact of SakSTAR on platelet aggregation, disaggregation, and ATP secretion.
• To compare the fibrinolytic activity of SakSTAR with streptokinase (SK) in vitro.

Main Methods:

• Experiments were conducted in buffer and human plasma milieus, including plasma from acute myocardial infarction (AMI) patients.
• Platelet aggregation and disaggregation were measured using ADP and collagen as agonists.
• ATP secretion and fibrin clot lysis (C50) were quantified using radiolabeled fibrin.

Main Results:

• SakSTAR exhibited very low specific binding to resting and activated platelets.
• SakSTAR did not significantly alter ADP- or collagen-induced platelet aggregation or disaggregation.
• SakSTAR demonstrated potent fibrin clot lysis, comparable to or exceeding streptokinase, especially in specific patient plasma.

Conclusions:

• Recombinant staphylokinase (SakSTAR) has minimal direct interaction with human platelets, suggesting a favorable safety profile regarding platelet function.
• SakSTAR effectively promotes fibrinolysis, indicating its potential as a therapeutic agent for thrombotic conditions.
• The study supports the use of SakSTAR in clinical settings, particularly for acute myocardial infarction (AMI) treatment.